Thursday, March 21, 2019

ProMIS Neurosciences (PMN:CA)

A door opens in the treatment for Alzheimer’s.

ProMIS Neurosciences,
Inc., a development stage biotech company, discovers and develops precision
medicine therapeutics for the treatment of neurodegenerative diseases,
primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its
proprietary target discovery engine is based on the use of two complementary
techniques. 

Cosme Ordoñez, M.D., Ph. D.

, Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating. 

• Competitor discontinues development. Biogen (BIIB: Not Rated), a competing company in the Alzheimer’s area,
  this morning announced the decision to discontinue clinical development of aducanumab.  Biogen is
  discontinuing two Phase III clinical trials evaluating the efficacy and safety
  of aducanumab for the treatment of Alzheimer’s patients. 
• Skepticism to heighten. We believe the negative news will fuel skepticism among
  investors looking to deploy capital in Alzheimer’s area. The failure of Biogen
  adds to a string of disappointing results in hum…
  

  
  
  
  
  

  Get full report on Channelchek desktop.

  
  
  

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.